作者
Mark G Kris, Bruce E Johnson, Lynne D Berry, David J Kwiatkowski, A John Iafrate, Ignacio I Wistuba, Marileila Varella-Garcia, Wilbur A Franklin, Samuel L Aronson, Pei-Fang Su, Yu Shyr, D Ross Camidge, Lecia V Sequist, Bonnie S Glisson, Fadlo R Khuri, Edward B Garon, William Pao, Charles Rudin, Joan Schiller, Eric B Haura, Mark Socinski, Keisuke Shirai, Heidi Chen, Giuseppe Giaccone, Marc Ladanyi, Kelly Kugler, John D Minna, Paul A Bunn
发表日期
2014/5/21
期刊
Jama
卷号
311
期号
19
页码范围
1998-2006
出版商
American Medical Association
简介
Importance
Targeting oncogenic drivers (genomic alterations critical to cancer development and maintenance) has transformed the care of patients with lung adenocarcinomas. The Lung Cancer Mutation Consortium was formed to perform multiplexed assays testing adenocarcinomas of the lung for drivers in 10 genes to enable clinicians to select targeted treatments and enroll patients into clinical trials.
Objectives
To determine the frequency of oncogenic drivers in patients with lung adenocarcinomas and to use the data to select treatments targeting the identified driver(s) and measure survival.
Design, Setting, and Participants
From 2009 through 2012, 14 sites in the United States enrolled patients with metastatic lung adenocarcinomas and a performance status of 0 through 2 and tested their tumors for 10 drivers. Information was collected on patients, therapies, and survival.
Interventions
Tumors were tested for 10 …
学术搜索中的文章
MG Kris, BE Johnson, LD Berry, DJ Kwiatkowski… - Jama, 2014